AgomAb Therapeutics (NASDAQ:AGMB) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $60.00 price target on the stock.

A number of other equities research analysts have also issued reports on AGMB. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright started coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, B. Riley Financial initiated coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.50.

AgomAb Therapeutics Trading Up 9.4%

Shares of NASDAQ:AGMB opened at $14.02 on Tuesday. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.82. The firm’s 50 day moving average price is $13.02.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, equities research analysts predict that AgomAb Therapeutics will post -1.71 EPS for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.